Stock listing

NASDAQ:ERNA Ernexa Therapeutics Inc. Stock

Home listing (NASDAQ) of Ernexa Therapeutics Inc.

Follow Ernexa Therapeutics Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ERNA

$1.36 USD -0.26 (-16.0%)

Close on Nov 20, 2026

Past year -95.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.35 – $1.60 USDNov 20, 2026
Volume
20,382 sharesNov 20, 2026
Market cap
$2.30M USDAt the close on Nov 20, 2026 · price × 1.69M shares outstanding
52-week range
$1.35 – $37.50 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$140,241 USDMedian day 20,382 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Ernexa Therapeutics Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ERNA · Home$1.36 USD-0.26 (-16.0%)20,382$1.60$1.60$1.35$1.62Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ERNA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.36-0.26-16.0%$1.60$1.60$1.3520,382
$1.62-0.01-0.6%$1.64$1.713$1.6014,752
$1.63-0.06-3.6%$1.65$1.822$1.5726,221
$1.69+0.01+0.6%$1.80$1.80$1.6920,359
$1.68-0.11-6.1%$1.82$1.94$1.6728,254
$1.79-0.14-7.3%$1.87$2.04$1.73423,989
$1.93-0.08-4.0%$2.053$2.053$1.909,815
$2.01-0.04-2.0%$1.98$2.04$1.9013,321
$2.05+0.17+9.0%$1.87$2.05$1.75528,402
$1.88+0.05+2.7%$1.78$1.895$1.787,913
$1.83-0.16-8.0%$2.05$2.05$1.7433,732
$1.99-0.03-1.5%$1.98$2.04$1.9417,332
$2.02+0.07+3.6%$2.075$2.123$1.9911,368
$1.95-0.02-1.0%$2.04$2.04$1.938,999
$1.97-0.14-6.6%$2.08$2.14$1.954,493
$2.11+0.13+6.6%$2.03$2.11$1.9987,265
$1.98-0.013-0.7%$1.91$2.03$1.913,471
$1.993+0.055+2.8%$2.12$2.12$1.967,436
$1.938-0.127-6.2%$1.98$2.08$1.9211,182
$2.065-0.01-0.5%$2.075$2.09$2.035,931
$2.075-0.035-1.7%$2.095$2.125$1.9816,467
$2.11-0.13-5.8%$2.19$2.255$2.089,569
$2.24+0.26+13.1%$1.96$2.26$1.8948,186
$1.98-0.11-5.3%$2.04$2.07$1.83944,353
$2.09-0.08-3.7%$2.17$2.23$2.0424,617
$2.17+0.06+2.8%$2.10$2.23$2.057,004
$2.11-0.10-4.5%$2.20$2.20$2.01310,300
$2.210.000.0%$2.19$2.24$2.188,312
$2.21-0.19-7.9%$2.40$2.40$2.12530,705
$2.40-0.09-3.6%$2.45$2.49$2.2546,599
$2.49+0.10+4.2%$2.40$2.70$2.12214,740
$2.39+0.155+6.9%$2.25$2.39$2.15662,923
$2.235-0.465-17.2%$2.75$2.96$2.2091,550
$2.70-0.26-8.8%$3.04$3.058$2.7021,552
$2.960.000.0%$3.00$3.28$2.9040,810
$2.96-0.24-7.5%$3.13$3.236$2.8435,741
$3.20+0.04+1.3%$3.24$3.47$3.1642,635
$3.16-0.31-8.9%$3.738$3.738$3.04461,865
$3.47+0.025+0.7%$3.46$3.50$3.2025,791
$3.445-0.175-4.8%$3.73$3.848$3.4021,417
$3.62-0.03-0.8%$3.785$3.821$3.6111,526
$3.65-0.15-3.9%$3.73$3.79$3.656,237
$3.80-0.16-4.0%$3.96$3.96$3.7614,663
$3.96+0.13+3.4%$4.01$4.01$3.7513,500
$3.83+0.07+1.9%$3.79$3.885$3.798,276
$3.76-0.15-3.8%$4.04$4.08$3.71533,601
$3.91-0.17-4.2%$4.01$4.155$3.8422,562
$4.08-0.19-4.4%$3.79$4.70$3.65547,184
$4.27+0.105+2.5%$4.13$4.40$4.1316,826
$4.165+0.145+3.6%$4.05$4.42$4.0319,816
$4.020.000.0%$3.925$4.05$3.9011,381
$4.02-0.17-4.1%$4.20$4.23$3.9715,648
$4.19-0.12-2.8%$4.31$4.34$4.1318,298
$4.31-0.22-4.9%$4.50$4.83$4.2147,568
$4.53-0.01-0.2%$4.494$4.728$4.4014,673
$4.54+0.19+4.4%$4.42$4.804$4.4023,297
$4.35-0.22-4.8%$4.57$4.65$4.2629,517
$4.570.000.0%$4.68$4.75$4.549,638
$4.57-0.165-3.5%$4.76$4.99$4.5626,720
$4.735-0.155-3.2%$4.77$4.93$4.5641,081
$4.89-0.035-0.7%$4.82$4.932$4.7515,092
$4.925-0.11-2.2%$5.00$5.51$4.89481,862
$5.035+0.175+3.6%$4.86$5.15$4.7522,643
$4.86+0.34+7.5%$4.53$5.198$4.5371,125
$4.52+0.09+2.0%$4.34$4.76$4.3427,832

Splits

4 splits since 2021 · NASDAQ:ERNA · every price before a split is adjusted for it

DayRatioWhat
1-for-25Consolidation
1-for-15Consolidation
1-for-20Consolidation
1-for-2Consolidation
Ticker
NASDAQ:ERNA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Ernexa Therapeutics Inc. news

Ernexa Therapeutics Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
27 in the last 12 months · 72 in all · newest Oct 22, 2026 · oldest 2022
Decks
12 decks · latest Oct 15, 2026

Where Ernexa Therapeutics Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ERNA · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ERNABOATSUnited StatesUSD

Valuation

Price/book 0.5× against a median of 0.4×: 6th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$2.96M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.5×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.1×
Beta vs S&P 500
0.86

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Ernexa Therapeutics Inc. · NASDAQ:ERNAUS$2.30M−US$2.96Mn/an/an/a0.5×n/a0.1×0.86
ValiRx PLC · LSE:VALUS$2.42MUS$1.15Mn/a28.0×n/a0.6×n/a0.0×n/a
BSF Enterprise PLC · LSE:BSFAUS$2.40MUS$2.95Mn/a42.7×n/a1.0×n/a0.3×n/a
Revelation Biosciences, Inc. · NASDAQ:REVBUS$2.39M−US$5.92Mn/an/an/a0.3×n/a0.1×1.66
Mustang Bio, Inc. · NASDAQ:MBIOUS$2.38M−US$11.89Mn/an/an/a0.4×n/a0.0×1.01
Quest PharmaTech Inc. · TSXV:QPTUS$2.36MUS$2.30M0.7×n/an/a0.1×n/a0.0×1.90
HCW Biologics Inc. · NASDAQ:HCWBUS$2.35MUS$8.23Mn/a1.2×n/a0.3×−63.4%1.0×1.19
Cynata Therapeutics Limited · ASX:CYPUS$2.26MUS$1.66Mn/a1.5×n/an/a−540.4%n/an/a
PharmaCyte Biotech, Inc. · NASDAQ:PMCBUS$2.25M−US$15.59Mn/an/an/a0.1×n/a0.0×1.97
Modus Therapeutics Holding AB · OMXSTO:MODTXUS$2.22MUS$1.00Mn/an/an/a2.2×n/a0.0×n/a
Nuformix PLC · LSE:NFXUS$2.22MUS$1.00Mn/an/an/a1.0×n/a0.0×n/a
Median of the othersUS$2.36MUS$1.08M0.7×14.7×0.4×−301.9%0.0×1.66

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.

Price target
30.00 USD · Analysts' mean
EPS, year to Dec 2026
-18.02 · 1 analyst

Team and board

Officers

OfficerRole
Sanjeev LutherPresident and CEO
Mark J. KeeleyChief Financial Officer
Dorothy ClarkeGeneral Counsel
Deborah WildHead of CMC and Operations
Marc C. ChamberlainChief Medical Officer
Robert PierceChief Scientific Officer

Board

DirectorRole
James BristolChairman
Bill WexlerDirector
David PolinskyDirector
Elena RatnerDirector
Peter CicalaDirector
Robert J. SpiegelDirector

Events

QuarterResultsShare move
Q3 2026Nov 6, 2026 · After close+9.0%
Q2 2026Aug 12, 2026−2.0%
Q1 2026May 11, 2026 · After close+66.6%
Q4 2025Mar 24, 2026−10.4%
Q3 2025Nov 7, 2025−1.2%
Q2 2025Aug 13, 2025−4.1%
Q1 2025May 7, 2025−3.9%
Q4 2024Mar 12, 2025−4.9%
Q3 2024Nov 29, 2024−9.1%
Q2 2024Aug 12, 2024+4.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 22, 2024−5.4%
Q4 2023Mar 19, 2024−6.0%
Q3 2023Nov 13, 2023 · Before open−2.5%
Q2 2023Aug 11, 2023 · After close−0.4%
Q1 2023May 11, 2023 · After close−2.3%
Q4 2022Mar 20, 2023 · Before open−7.7%
Q3 2022Nov 14, 2022 · After close−1.1%
Q2 2022Aug 11, 2022 · After close+2.6%
Q1 2022Apr 15, 2022 · After close−11.6%
Quarter to Sep 30, 2021Nov 12, 2021 · After close−0.7%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck19 slidesOct 15, 2026
Investor Presentation (October 2026)Investor deck19 slidesOct 15, 2026
Investor Presentation (September 2026)Investor deck17 slidesSeptember 2026
Investor Presentation (July 2026)Investor deck24 slidesJul 2, 2026
Investor Presentation (February 2026)Investor deck33 slidesFeb 26, 2026
Investor Presentation (December 2025)Investor deck31 slidesDec 11, 2025
Eterna Therapeutics — Investor Presentation (August 2023)Investor deck18 slidesAug 2, 2023
Eterna Therapeutics — Investor Presentation (November 2022)Investor deck15 slidesNov 9, 2022
Brooklyn ImmunoTherapeutics — Investor Presentation (November 2021)Investor deck30 slidesNov 12, 2021
Brooklyn ImmunoTherapeutics — Investor Presentation (September 2021)Investor deck21 slidesSep 20, 2021
All 12 decks
DeckKindSlidesDate
Brooklyn ImmunoTherapeutics — Investor Presentation (September 2021)Investor deck9 slidesSep 9, 2021
Brooklyn ImmunoTherapeutics — Merger or Acquisition (July 2021)Merger or acquisition13 slidesJul 19, 2021

Open Decks

Financings

RaiseDate
Public offering of shares of common stock (or common stock equivalents) and accompanying warrants
Announced: about US$10.5M · US$0.5 a share · Warrants at US$0.68 · Brookline Capital Markets, a division of Arcadia Securities, LLC
Dealers: Brookline Capital Markets, a division of Arcadia Securities, LLC (lead)
Use of proceeds: Advancement of its development programs, working capital and general corporate purposes
Feb 6, 2026
Private placement of shares of common stock and pre-funded warrants
Tranche closed: US$7.1M raised · US$0.1046 a share
Use of proceeds: General working capital and repayment of certain notes
Jun 24, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0582.0K68.0K005.80M19.8M23.3M21.3M22.3M
Cost of revenue263.0K96.0K236.0K0459.0K98.0K7.84M8.38M7.09M8.13M
Gross profit-263.0K486.0K-168.0K0-459.0K-98.0K12.0M14.9M14.2M14.2M
Research and development4.16M4.60M5.92M10.4M12.7M2.00K26.0K72.0K139.0K
Selling, general and administrative5.16M13.1M14.6M16.6M14.7M8.09M13.2M14.5M15.6M16.5M
Operating income-9.32M-15.7M-21.1M-33.2M-113.7M-7.25M-1.76M203.0K-1.40M-2.28M
Depreciation and amortization65.0K139.0K84.0K161.0K117.0K98.0K2.88M2.76M2.32M2.89M
EBITDA-9.25M-15.5M-21.1M-33.1M-113.6M-7.15M1.11M2.97M915.0K609.0K
Interest expense-100.0K-6.80M614.0K30.0K74.0K118.0K236.0K296.0K425.0K517.0K
Income before tax-14.1M-44.5M-21.7M-24.5M-122.5M-7.29M-2.02M-323.0K-1.01M-2.88M
Income tax-45.0K30.0K-3.00K45.0K64.0K027.0K-64.0K66.0K38.0K
Net income-14.1M-44.5M-21.7M-24.6M-122.5M-7.29M-2.05M-259.0K-1.08M-2.92M
Earnings per share, basic-2.24-48.96-4.08-8.06-56.61-0.41-0.72-0.10-0.45-1.54
Earnings per share, diluted-2.24-48.96-4.08-8.06-56.61-0.41-0.72-0.10-0.45-1.54

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents1.88M1.73M7.58M11.4M17.0M777.0K3.21M2.54M3.38M5.69M
Receivables95.0K437.0K425.0K951.0K684.0K01.20M1.14M714.0K928.0K
Inventory-951.0K-116.0K1.09M2.54M4.87M3.00M
Current assets3.13M2.35M9.60M13.7M18.8M1.73M6.07M6.79M9.64M10.7M
Property, plant and equipment94.0K85.0K493.0K236.0K670.0K594.0K2.82M4.67M3.68M3.10M
Goodwill2.04M2.04M2.04M2.04M2.04M2.04M696.0K667.0K1.00M937.0K
Total assets5.83M5.27M49.1M22.3M31.5M12.9M14.1M14.9M16.6M16.7M
Accounts payable1.13M1.72M1.07M1.62M1.75M1.27M835.0K271.0K390.0K247.0K
Current liabilities3.11M2.94M6.57M7.65M3.68M3.13M6.09M4.02M10.7M6.64M
Long-term debt6.77M1.21M532.0K
Total debt490.0K684.0K41.8M4.14M2.72M2.03M2.74M3.75M5.12M8.11M
Total liabilities3.43M3.57M46.9M10.2M6.02M5.25M9.03M7.95M11.0M12.6M
Shareholders' equity2.40M1.70M2.23M12.1M25.5M7.66M9.74M6.92M5.54M4.07M
Shares outstanding314.0K3.43M5.41M5.13M2.60M02.90M2.88M2.52M2.26M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-7.02M-15.8M-20.4M-21.0M-23.5M-8.10M2.74M1.36M549.0K23.0K
Capital spending-37.0K-369.0K-19.0K-297.0K-154.0K-39.0K-128.0K-648.0K-728.0K-427.0K
Free cash flow-7.05M-16.2M-20.4M-21.3M-23.6M-8.14M2.62M717.0K-179.0K-404.0K
Cash from investing-37.0K-365.0K-19.0K-47.0K-22.7M-39.0K-1.06M-1.58M-1.45M-840.0K
Cash from financing7.21M6.26M16.6M19.6M61.6M4.67M-1.10M-303.0K-1.47M3.26M
Dividends paid-16.0K-16.0K-16.0K-8.00K-16.0K-16.0K-16.0K-16.0K-16.0K
Share buybacks-16.3M-22.9M35.0K
Change in cash155.0K-9.94M-3.87M-1.44M15.4M-2.63M623.0K-592.0K-2.37M2.44M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 19, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 10, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 30, 2026Big-stake noticeSEC
8-K · Current reportOct 15, 2026Current reportSEC
3 · Initial statement of ownershipSep 22, 2026Insider tradeSEC
8-K · Current reportSep 16, 2026Current reportSEC
8-K · Current reportSep 16, 2026Management or board changeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipSep 1, 2026Insider tradeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 27, 2026Insider tradeSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportJul 2, 2026Current reportSEC
8-K · Current reportJul 2, 2026Meeting outcomeSEC
8-K · Current reportJun 26, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 20, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersMay 11, 2026Annual reportSEC
DEFA14A · Additional proxy materialMay 11, 2026Meeting noticeSEC
DEF 14A · Proxy statementMay 11, 2026Meeting noticeSEC
10-Q · Quarterly reportMay 11, 2026Quarterly reportSEC
8-K · Current reportMay 4, 2026Current reportSEC
DEF 14CApr 13, 2026Meeting noticeSEC
PRE 14CApr 1, 2026Meeting noticeSEC
EFFECT · Notice that a registration is effectiveMar 31, 2026Other filingsSEC
CORRESP · Letter to the SECMar 26, 2026Other filingsSEC
S-3/A · Registration statement, amendedMar 24, 2026Offer documentSEC
8-K · Current reportMar 20, 2026Current reportSEC
UPLOAD · Letter from the SECMar 20, 2026Other filingsSEC
S-3 · Registration statementMar 13, 2026Offer documentSEC
10-K · Annual reportMar 13, 2026Annual reportSEC
8-K · Current reportFeb 26, 2026Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
8-K · Current reportFeb 11, 2026Material contractSEC
424B5 · ProspectusFeb 10, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveFeb 6, 2026Other filingsSEC
CERT · Exchange's certificate of listingFeb 5, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeFeb 5, 2026Other filingsSEC
S-1/A · Registration statement, amendedFeb 5, 2026Offer documentSEC
S-1/A · Registration statement, amendedFeb 3, 2026Offer documentSEC
CORRESP · Letter to the SECFeb 3, 2026Other filingsSEC
CORRESP · Letter to the SECFeb 3, 2026Other filingsSEC
S-1 · Registration statementFeb 2, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 19, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 16, 2025Big-stake noticeSEC
8-K · Current reportDec 11, 2025Current reportSEC
10-Q · Quarterly reportNov 7, 2025Quarterly reportSEC
DRSLTR · Letter to the SEC with a draftOct 22, 2025Other filingsSEC
DRS · Draft registration statementOct 22, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 18, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
4 · Change in ownershipJul 7, 2025Insider tradeSEC
8-K · Current reportJul 7, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveJun 20, 2025Other filingsSEC
424B3 · ProspectusJun 18, 2025Offer documentSEC
CORRESP · Letter to the SECJun 16, 2025Other filingsSEC
UPLOAD · Letter from the SECJun 16, 2025Other filingsSEC
8-K · Current reportJun 12, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 11, 2025Big-stake noticeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
S-8 · Registration statement for employee plansJun 11, 2025Offer documentSEC
S-3 · Registration statementJun 11, 2025Offer documentSEC
8-K · Current reportJun 9, 2025FinancingSEC
8-K · Current reportJun 2, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 7, 2025Quarterly reportSEC
4/A · Change in ownership, amendedMay 7, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveApr 30, 2025Other filingsSEC
424B3 · ProspectusApr 29, 2025Offer documentSEC
CORRESP · Letter to the SECApr 25, 2025Other filingsSEC
UPLOAD · Letter from the SECApr 25, 2025Other filingsSEC
S-3 · Registration statementApr 16, 2025Offer documentSEC
ARS · Annual report to shareholdersApr 14, 2025Annual reportSEC
DEF 14A · Proxy statementApr 14, 2025Meeting noticeSEC
DApr 11, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 4, 2025Big-stake noticeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
PRE 14A · Preliminary proxy statementApr 3, 2025Meeting noticeSEC
8-K · Current reportApr 3, 2025Material contractSEC
8-K · Current reportMar 26, 2025Current reportSEC
8-K · Current reportMar 24, 2025Material contractSEC
10-K · Annual reportMar 12, 2025Annual reportSEC
8-K · Current reportMar 12, 2025Material contractSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 5, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
8-K · Current reportFeb 13, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 10, 2025Insider tradeSEC
4 · Change in ownershipFeb 10, 2025Insider tradeSEC
4 · Change in ownershipFeb 10, 2025Insider tradeSEC
4 · Change in ownershipFeb 10, 2025Insider tradeSEC
4 · Change in ownershipFeb 10, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 28, 2025Big-stake noticeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 14, 2025Insider tradeSEC
8-K · Current reportJan 10, 2025Management or board changeSEC
8-K · Current reportJan 3, 2025Current reportSEC
424B3 · ProspectusNov 18, 2024Offer documentSEC
424B3 · ProspectusNov 18, 2024Offer documentSEC
424B3 · ProspectusNov 18, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveNov 18, 2024Other filingsSEC
DNov 14, 2024Other filingsSEC
DNov 14, 2024Other filingsSEC
CORRESP · Letter to the SECNov 13, 2024Other filingsSEC
UPLOAD · Letter from the SECNov 13, 2024Other filingsSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
S-1 · Registration statementNov 5, 2024Offer documentSEC
4 · Change in ownershipNov 5, 2024Insider tradeSEC
8-K · Current reportOct 29, 2024Material contractSEC
ARS · Annual report to shareholdersOct 16, 2024Annual reportSEC
DEF 14A · Proxy statementOct 7, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementSep 27, 2024Meeting noticeSEC
8-K · Current reportSep 27, 2024Material contractSEC
8-K · Current reportSep 25, 2024Material contractSEC
8-K · Current reportSep 23, 2024Current reportSEC
8-K · Current reportAug 19, 2024Current reportSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
4 · Change in ownershipJun 25, 2024Insider tradeSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
4 · Change in ownershipApr 29, 2024Insider tradeSEC
4 · Change in ownershipApr 29, 2024Insider tradeSEC
4 · Change in ownershipApr 29, 2024Insider tradeSEC
8-K · Current reportMar 22, 2024Current reportSEC
10-K/A · Annual report, amendedMar 18, 2024Annual reportSEC
10-K · Annual reportMar 14, 2024Annual reportSEC
3 · Initial statement of ownershipFeb 16, 2024Insider tradeSEC
8-K · Current reportFeb 16, 2024Management or board changeSEC
SC 13G/A · Big-stake notice, amendedJan 31, 2024Big-stake noticeSEC
424B3 · ProspectusJan 24, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 23, 2024Other filingsSEC
8-K · Current reportJan 19, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedJan 19, 2024Big-stake noticeSEC
CORRESP · Letter to the SECJan 18, 2024Other filingsSEC
UPLOAD · Letter from the SECJan 17, 2024Other filingsSEC
S-8 · Registration statement for employee plansJan 16, 2024Offer documentSEC
S-3 · Registration statementJan 12, 2024Offer documentSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 3, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedDec 22, 2023Big-stake noticeSEC
8-K · Current reportDec 20, 2023Material contractSEC
SC 13G · Big-stake noticeDec 20, 2023Big-stake noticeSEC
4 · Change in ownershipDec 20, 2023Insider tradeSEC
DDec 19, 2023Other filingsSEC
4 · Change in ownershipDec 18, 2023Insider tradeSEC
8-K · Current reportDec 14, 2023Material contractSEC
8-K · Current reportNov 16, 2023Material contractSEC
3 · Initial statement of ownershipNov 13, 2023Insider tradeSEC
10-Q · Quarterly reportNov 13, 2023Quarterly reportSEC
8-K · Current reportNov 1, 2023Management or board changeSEC
8-K · Current reportOct 5, 2023Management or board changeSEC
8-K/A · Current report, amendedSep 26, 2023Management or board changeSEC
SC 13G/A · Big-stake notice, amendedSep 8, 2023Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedSep 7, 2023Big-stake noticeSEC
3 · Initial statement of ownershipSep 1, 2023Insider tradeSEC
8-K · Current reportAug 31, 2023Management or board changeSEC
SC 13G · Big-stake noticeAug 28, 2023Big-stake noticeSEC
4 · Change in ownershipAug 25, 2023Insider tradeSEC
424B3 · ProspectusAug 23, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 23, 2023Other filingsSEC
CORRESP · Letter to the SECAug 18, 2023Other filingsSEC
UPLOAD · Letter from the SECAug 17, 2023Other filingsSEC
S-3 · Registration statementAug 14, 2023Offer documentSEC
10-Q · Quarterly reportAug 11, 2023Quarterly reportSEC
4 · Change in ownershipAug 10, 2023Insider tradeSEC
4 · Change in ownershipAug 10, 2023Insider tradeSEC
8-K · Current reportAug 10, 2023Management or board changeSEC
8-K · Current reportAug 2, 2023Current reportSEC
SC 13D/A · Big-stake notice, amendedJul 26, 2023Big-stake noticeSEC
DJul 26, 2023Other filingsSEC
DJul 26, 2023Other filingsSEC
SC 13G/A · Big-stake notice, amendedJul 20, 2023Big-stake noticeSEC
4 · Change in ownershipJul 18, 2023Insider tradeSEC
4 · Change in ownershipJul 18, 2023Insider tradeSEC
8-K · Current reportJul 18, 2023Material contractSEC
4 · Change in ownershipJul 18, 2023Insider tradeSEC
8-K · Current reportJul 13, 2023Material contractSEC
3 · Initial statement of ownershipJul 11, 2023Insider tradeSEC
3 · Initial statement of ownershipJul 11, 2023Insider tradeSEC
8-K · Current reportJul 11, 2023Management or board changeSEC
4 · Change in ownershipJun 23, 2023Insider tradeSEC
8-K · Current reportJun 20, 2023Meeting outcomeSEC
10-Q · Quarterly reportMay 11, 2023Quarterly reportSEC
DEFA14A · Additional proxy materialMay 9, 2023Meeting noticeSEC
ARS · Annual report to shareholdersMay 5, 2023Annual reportSEC
DEFA14A · Additional proxy materialMay 5, 2023Meeting noticeSEC
DEF 14A · Proxy statementMay 5, 2023Meeting noticeSEC

This page holds 200 of 1,001 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Ernexa Therapeutics Inc.’s releases · as of Nov 6, 2026

Common shares
1,692,550
Fully diluted
1,692,550

Fully diluted

LineSharesAs of
Common shares1,692,550Nov 6, 2026

Share count over time

CountShares
Nov 6, 20261,692,550

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Corient Private Wealth LP17,4611.0%US$55,876Sep 30, 2026
Geode Capital16,0770.95%US$51,446Sep 30, 2026
Vanguard14,0200.83%US$44,864Sep 30, 2026
Tradewinds Capital Management, LLC4,6090.27%US$14,749Sep 30, 2026
Tower Research Capital LLC (TRC)1,5520.09%US$4,966Sep 30, 2026
Morgan Stanley2000.01%US$640Sep 30, 2026
Citigroup Inc102<0.01%US$326Sep 30, 2026
BlackRock33<0.01%US$106Sep 30, 2026
UBS19<0.01%US$61Sep 30, 2026
Assetmark, Inc5<0.01%US$16Sep 30, 2026
All 14 holders
HolderSharesOf the companyValueAs of
Dauntless Investment Group, LLC1<0.01%US$3Sep 30, 2026
SBI Securities Co., Ltd.1<0.01%US$3Sep 30, 2026
BNP Paribas1<0.01%US$3Sep 30, 2026
Steward Partners Investment Advisory, LLC00.00%US$1Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Extended Market Index Fund5,6840.34%US$37,799Jun 30, 2026
Fidelity Extended Market Index Fund5,5740.33%US$58,917May 31, 2026
Fidelity Series Total Market Index Fund2,4140.14%US$25,516May 31, 2026
Blackstone Alternative Multi-Strategy Fund1<0.01%US$7Jun 30, 2026

Big stakes

StakeStakeSharesDateFiling
Regolith Capital Investments LP9.70%118KFeb 10, 2026Schedule 13G
Freebird Partners LP7.00%119KAug 5, 2026Schedule 13G
John D. Halpern5.60%66,751Feb 10, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Robert J. Spiegel
Other companies: RenovoRx, Inc. (Director · Since at least Apr 25, 2023); Geron Corporation (Director · Since at least Sep 29, 2017); Athenex Inc (Director · Aug 4, 2020 – Apr 21, 2023 · Past); Ayala Pharmaceuticals Inc (Director · May 7, 2020 – Jan 19, 2023 · Past); Bio Green Med Solution, Inc. (Director · Sep 6, 2018 – Jun 30, 2023 · Past); PDS Biotechnology Corporation (Director · Jun 19, 2018 – Mar 15, 2019 · Past); Sucampo Pharmaceuticals Inc (Director · Feb 13, 2018 – Feb 13, 2018 · Past)
Director · Since at least Sep 14, 2026
Dennis Langer
Other companies: Quoin Pharmaceuticals. Ltd (Director · Since at least Jan 1, 2023); Pernix Therapeutics Holdings Inc (Director · Nov 4, 2016 – May 22, 2018 · Past); Delcath Systems, Inc. (Director · Dec 11, 2014 – Jun 10, 2015 · Past); Dicerna Pharmaceuticals Inc (Director · Sep 24, 2013 – Jun 20, 2019 · Past); Myrexis Inc (Director · Dec 8, 2011 – Dec 8, 2011 · Past); Myriad Genetics, Inc. (Director · Dec 2, 2011 – Jun 30, 2022 · Past)
Director · May 1, 2021 – Dec 8, 2021 · Past
James Bristol
Other companies: Erasca, Inc. (Director · Since at least Jan 1, 2024); Deciphera Pharmaceuticals LLC (Director · Jun 11, 2024 – Jun 11, 2024 · Past)
Chairman · Since at least Oct 30, 2023
Luba Greenwood
Other companies: IN8bio, Inc. (Director · Since at least Jul 29, 2021); Traws Pharma, Inc. (Director · Sep 16, 2024 – Sep 16, 2024 · Past)
Director · Mar 25, 2021 – Dec 8, 2021 · Past
Charles Cherington
Other companies: Beard Energy Transition Acquisition Corp (Director · Nov 23, 2021 – Nov 23, 2021 · Past)
Director · Mar 25, 2021 – Dec 2, 2022 · Past
David Polinsky
Other companies: Rafael Holdings, Inc. (Chief Financial Officer · Since at least Oct 25, 2023)
Director · Since at least Aug 4, 2026
Erin S Enright
Other companies: Amarin Corporation plc (Director · May 16, 2022 – Jun 27, 2022 · Past)
Director · Jan 14, 2022 – Jan 14, 2022 · Past
Matthew Angel
Other companies: Tempest Therapeutics, Inc. (CEO and President, Director · Since at least Feb 3, 2026)
President and CEO, Director · May 26, 2022 – Jan 12, 2023 · Past
Roger Sidhu
Other companies: Cardiff Oncology, Inc. (Chief Medical Officer · Since at least Jun 16, 2025)
Chief Medical Officer · Sep 20, 2021 – Sep 20, 2022 · Past
Bill WexlerDirector · Since at least Nov 4, 2026
All 40 people
PersonSeat
Brant BinderDirector · Jul 6, 2023 – Jul 14, 2023 · Past
Christopher Allen GeorgeChief Information Officer · Aug 6, 2012 – Aug 6, 2012 · Past
C Kirk ReadDirector · Sep 13, 2007 – Sep 13, 2007 · Past
Deborah WildHead of CMC and Operations · Since at least Nov 5, 2026
Dorothy ClarkeGeneral Counsel · Since at least Nov 5, 2026
Elena RatnerDirector · Since at least May 20, 2026
George P Denny IIIDirector · Mar 25, 2021 – Mar 25, 2021 · Past
Gregory FioreDirector · Jun 5, 2022 – Aug 1, 2022 · Past
Gregory Matthew ThomasDirector · Jun 7, 2019 – Jun 7, 2019 · Past
Jay SialChief Administration Officer · Jul 15, 2021 – Mar 11, 2022 · Past
John GaffneySr. V.P. Product Management · Feb 1, 2008 – Feb 4, 2008 · Past
Joseph J Farricielli JrDirector · Dec 18, 2007 – Jun 15, 2009 · Past
Kartik V RamachandranChief Strat Off, EVP Bus Dev · Apr 24, 2009 – Apr 24, 2009 · Past
Kevin DAmourChief Scientific Officer · Jun 28, 2021 – Jun 28, 2022 · Past
Kirk NagamineChief Revenue Officer · Apr 15, 2013 – Apr 15, 2013 · Past
Lynn Sadowski MasonSee Remarks · Mar 25, 2021 – Mar 25, 2021 · Past
Marc C. ChamberlainChief Medical Officer · Since at least Nov 5, 2026
Mariana DanilovicEx. VP, Business Development · Aug 14, 2007 – Aug 14, 2007 · Past
Mark J. KeeleyChief Financial Officer · Since at least Nov 5, 2026
Mary Beth LewisDirector · Feb 13, 2009 – Jun 8, 2017 · Past
Michael GottliebDirector · Nov 26, 2019 – Nov 26, 2019 · Past
Peter CicalaDirector · Since at least Nov 5, 2026
Ram KrishnanCEO, Director · Mar 19, 2018 – Aug 27, 2019 · Past
Richard W WagnerDirector · Jul 6, 2023 – Jul 14, 2023 · Past
Robert PierceChief Scientific Officer · Since at least Oct 22, 2026
Ronald GuidoSee Remarks · Mar 25, 2021 – Mar 25, 2021 · Past
Sanjeev LutherPresident and CEO · Since at least Jan 1, 2024
Steve MitgangDirector · Aug 1, 2010 – Jun 7, 2019 · Past
William A WexlerDirector · Since at least Jun 5, 2022
Yiannis MonovoukasDirector · Mar 25, 2021 – Mar 25, 2021 · Past

Open People

Log in to ask 6ix AI your own questions about Ernexa Therapeutics Inc.